Short Interest in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Grows By 5.8%

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 10,420,000 shares, a growth of 5.8% from the September 30th total of 9,850,000 shares. Currently, 8.3% of the company’s stock are sold short. Based on an average trading volume of 1,330,000 shares, the days-to-cover ratio is currently 7.8 days.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares of the company’s stock, valued at $4,031,729.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Halozyme Therapeutics news, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares of the company’s stock, valued at $4,031,729.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Matthew L. Posard sold 10,000 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $55.72, for a total transaction of $557,200.00. Following the completion of the sale, the director now directly owns 89,755 shares of the company’s stock, valued at $5,001,148.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 89,881 shares of company stock valued at $5,169,834 over the last 90 days. 2.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Foster & Motley Inc. purchased a new position in Halozyme Therapeutics in the 3rd quarter worth about $609,000. Catalyst Capital Advisors LLC acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth about $1,944,000. QRG Capital Management Inc. acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth about $245,000. Janney Montgomery Scott LLC boosted its position in Halozyme Therapeutics by 38.4% during the 3rd quarter. Janney Montgomery Scott LLC now owns 36,020 shares of the biopharmaceutical company’s stock worth $2,062,000 after acquiring an additional 9,995 shares during the period. Finally, VELA Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $729,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

HALO stock opened at $50.59 on Thursday. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. The stock has a market capitalization of $6.44 billion, a price-to-earnings ratio of 20.90, a PEG ratio of 0.50 and a beta of 1.27. Halozyme Therapeutics has a 1 year low of $33.07 and a 1 year high of $65.53. The stock’s fifty day moving average is $57.56 and its two-hundred day moving average is $51.83.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business had revenue of $231.40 million for the quarter, compared to analysts’ expectations of $204.94 million. During the same period in the previous year, the business earned $0.68 earnings per share. The company’s revenue was up 4.7% on a year-over-year basis. On average, research analysts predict that Halozyme Therapeutics will post 3.71 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on HALO shares. Benchmark reissued a “buy” rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. The Goldman Sachs Group raised their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. TD Cowen raised their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, Morgan Stanley raised their price target on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $60.44.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.